Evaluating cryoablation of metastatic lung tumors in patients-safety and efficacy the ECLIPSE trial-interim analysis at 1 year

Thierry De Baere, Lambros Tselikas, David A Woodrum, Fereidoun Abtin, Peter Littrup, Frederic Deschamps, Robert Suh, Hussein D. Aoun, Matthew R Callstrom

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Introduction: To assess the feasibility, safety and local tumor control of cryoablation for treatment of pulmonary metastases. Materials and Methods: This Health Insurance Portability and Accountability Act (HIPAA) compliant, IRB-approved, multicenter, prospective, single arm study included 40 patients with 60 lung metastases treated during 48 cryoablation sessions, with currently a minimum of 12 months of follow-up. Patients were enrolled according to the following key inclusion criteria: 1 to 5 metastases from extrapulmonary cancers, with a maximal diameter of 3.5 cm. Local tumor control, disease-specific and overall survival rates were estimated using the Kaplan-Meier method. Complications and changes in physical function and quality of life were also evaluated using Karnofsky performance scale, Eastern Cooperative Oncology Group performance status classification, and Short Form-12 health survey. Results: Patients were 62.6 ± 13.3 years old (26-83). The most common primary cancers were colon (40%), kidney (23%), and sarcomas (8%). Mean size of metastases was 1.4 ± 0.7 cm (0.3-3.4), and metastases were bilateral in 20% of patients. Cryoablation was performed under general anesthesia (67%) or conscious sedation (33%). Local tumor control rates were 56 of 58 (96.6%) and 49 of 52 (94.2%) at 6 and 12 months, respectively. Patient's quality of life was unchanged over the follow-up period. One-year overall survival rate was 97.5%. The rate of pneumothorax requiring chest tube insertion was 18.8%. There were three Common Terminology Criteria for Adverse Events grade 3 procedural complications during the immediate follow-up period (pneumothorax requiring pleurodesis, noncardiac chest pain, and thrombosis of an arteriovenous fistula), with no grade 4 or 5 complications. Conclusion: Cryoablation is a safe and effective treatment for pulmonary metastases with preserved quality of life following intervention.

Original languageEnglish (US)
Pages (from-to)1468-1474
Number of pages7
JournalJournal of Thoracic Oncology
Volume10
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Cryosurgery
Patient Safety
Neoplasm Metastasis
Lung
Neoplasms
Quality of Life
Pneumothorax
Survival Rate
Pleurodesis
Health Insurance Portability and Accountability Act
Conscious Sedation
Karnofsky Performance Status
Chest Tubes
Research Ethics Committees
Arteriovenous Fistula
Health Surveys
Chest Pain
Terminology
Sarcoma
Colonic Neoplasms

Keywords

  • Cryoablation
  • Lung metastasis
  • Percutaneous ablation
  • Safety
  • Tumor control

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Evaluating cryoablation of metastatic lung tumors in patients-safety and efficacy the ECLIPSE trial-interim analysis at 1 year. / De Baere, Thierry; Tselikas, Lambros; Woodrum, David A; Abtin, Fereidoun; Littrup, Peter; Deschamps, Frederic; Suh, Robert; Aoun, Hussein D.; Callstrom, Matthew R.

In: Journal of Thoracic Oncology, Vol. 10, No. 10, 01.10.2015, p. 1468-1474.

Research output: Contribution to journalArticle

De Baere, Thierry ; Tselikas, Lambros ; Woodrum, David A ; Abtin, Fereidoun ; Littrup, Peter ; Deschamps, Frederic ; Suh, Robert ; Aoun, Hussein D. ; Callstrom, Matthew R. / Evaluating cryoablation of metastatic lung tumors in patients-safety and efficacy the ECLIPSE trial-interim analysis at 1 year. In: Journal of Thoracic Oncology. 2015 ; Vol. 10, No. 10. pp. 1468-1474.
@article{804339a974c442dca5b52014df6ede77,
title = "Evaluating cryoablation of metastatic lung tumors in patients-safety and efficacy the ECLIPSE trial-interim analysis at 1 year",
abstract = "Introduction: To assess the feasibility, safety and local tumor control of cryoablation for treatment of pulmonary metastases. Materials and Methods: This Health Insurance Portability and Accountability Act (HIPAA) compliant, IRB-approved, multicenter, prospective, single arm study included 40 patients with 60 lung metastases treated during 48 cryoablation sessions, with currently a minimum of 12 months of follow-up. Patients were enrolled according to the following key inclusion criteria: 1 to 5 metastases from extrapulmonary cancers, with a maximal diameter of 3.5 cm. Local tumor control, disease-specific and overall survival rates were estimated using the Kaplan-Meier method. Complications and changes in physical function and quality of life were also evaluated using Karnofsky performance scale, Eastern Cooperative Oncology Group performance status classification, and Short Form-12 health survey. Results: Patients were 62.6 ± 13.3 years old (26-83). The most common primary cancers were colon (40{\%}), kidney (23{\%}), and sarcomas (8{\%}). Mean size of metastases was 1.4 ± 0.7 cm (0.3-3.4), and metastases were bilateral in 20{\%} of patients. Cryoablation was performed under general anesthesia (67{\%}) or conscious sedation (33{\%}). Local tumor control rates were 56 of 58 (96.6{\%}) and 49 of 52 (94.2{\%}) at 6 and 12 months, respectively. Patient's quality of life was unchanged over the follow-up period. One-year overall survival rate was 97.5{\%}. The rate of pneumothorax requiring chest tube insertion was 18.8{\%}. There were three Common Terminology Criteria for Adverse Events grade 3 procedural complications during the immediate follow-up period (pneumothorax requiring pleurodesis, noncardiac chest pain, and thrombosis of an arteriovenous fistula), with no grade 4 or 5 complications. Conclusion: Cryoablation is a safe and effective treatment for pulmonary metastases with preserved quality of life following intervention.",
keywords = "Cryoablation, Lung metastasis, Percutaneous ablation, Safety, Tumor control",
author = "{De Baere}, Thierry and Lambros Tselikas and Woodrum, {David A} and Fereidoun Abtin and Peter Littrup and Frederic Deschamps and Robert Suh and Aoun, {Hussein D.} and Callstrom, {Matthew R}",
year = "2015",
month = "10",
day = "1",
doi = "10.1097/JTO.0000000000000632",
language = "English (US)",
volume = "10",
pages = "1468--1474",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "10",

}

TY - JOUR

T1 - Evaluating cryoablation of metastatic lung tumors in patients-safety and efficacy the ECLIPSE trial-interim analysis at 1 year

AU - De Baere, Thierry

AU - Tselikas, Lambros

AU - Woodrum, David A

AU - Abtin, Fereidoun

AU - Littrup, Peter

AU - Deschamps, Frederic

AU - Suh, Robert

AU - Aoun, Hussein D.

AU - Callstrom, Matthew R

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Introduction: To assess the feasibility, safety and local tumor control of cryoablation for treatment of pulmonary metastases. Materials and Methods: This Health Insurance Portability and Accountability Act (HIPAA) compliant, IRB-approved, multicenter, prospective, single arm study included 40 patients with 60 lung metastases treated during 48 cryoablation sessions, with currently a minimum of 12 months of follow-up. Patients were enrolled according to the following key inclusion criteria: 1 to 5 metastases from extrapulmonary cancers, with a maximal diameter of 3.5 cm. Local tumor control, disease-specific and overall survival rates were estimated using the Kaplan-Meier method. Complications and changes in physical function and quality of life were also evaluated using Karnofsky performance scale, Eastern Cooperative Oncology Group performance status classification, and Short Form-12 health survey. Results: Patients were 62.6 ± 13.3 years old (26-83). The most common primary cancers were colon (40%), kidney (23%), and sarcomas (8%). Mean size of metastases was 1.4 ± 0.7 cm (0.3-3.4), and metastases were bilateral in 20% of patients. Cryoablation was performed under general anesthesia (67%) or conscious sedation (33%). Local tumor control rates were 56 of 58 (96.6%) and 49 of 52 (94.2%) at 6 and 12 months, respectively. Patient's quality of life was unchanged over the follow-up period. One-year overall survival rate was 97.5%. The rate of pneumothorax requiring chest tube insertion was 18.8%. There were three Common Terminology Criteria for Adverse Events grade 3 procedural complications during the immediate follow-up period (pneumothorax requiring pleurodesis, noncardiac chest pain, and thrombosis of an arteriovenous fistula), with no grade 4 or 5 complications. Conclusion: Cryoablation is a safe and effective treatment for pulmonary metastases with preserved quality of life following intervention.

AB - Introduction: To assess the feasibility, safety and local tumor control of cryoablation for treatment of pulmonary metastases. Materials and Methods: This Health Insurance Portability and Accountability Act (HIPAA) compliant, IRB-approved, multicenter, prospective, single arm study included 40 patients with 60 lung metastases treated during 48 cryoablation sessions, with currently a minimum of 12 months of follow-up. Patients were enrolled according to the following key inclusion criteria: 1 to 5 metastases from extrapulmonary cancers, with a maximal diameter of 3.5 cm. Local tumor control, disease-specific and overall survival rates were estimated using the Kaplan-Meier method. Complications and changes in physical function and quality of life were also evaluated using Karnofsky performance scale, Eastern Cooperative Oncology Group performance status classification, and Short Form-12 health survey. Results: Patients were 62.6 ± 13.3 years old (26-83). The most common primary cancers were colon (40%), kidney (23%), and sarcomas (8%). Mean size of metastases was 1.4 ± 0.7 cm (0.3-3.4), and metastases were bilateral in 20% of patients. Cryoablation was performed under general anesthesia (67%) or conscious sedation (33%). Local tumor control rates were 56 of 58 (96.6%) and 49 of 52 (94.2%) at 6 and 12 months, respectively. Patient's quality of life was unchanged over the follow-up period. One-year overall survival rate was 97.5%. The rate of pneumothorax requiring chest tube insertion was 18.8%. There were three Common Terminology Criteria for Adverse Events grade 3 procedural complications during the immediate follow-up period (pneumothorax requiring pleurodesis, noncardiac chest pain, and thrombosis of an arteriovenous fistula), with no grade 4 or 5 complications. Conclusion: Cryoablation is a safe and effective treatment for pulmonary metastases with preserved quality of life following intervention.

KW - Cryoablation

KW - Lung metastasis

KW - Percutaneous ablation

KW - Safety

KW - Tumor control

UR - http://www.scopus.com/inward/record.url?scp=84942516354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942516354&partnerID=8YFLogxK

U2 - 10.1097/JTO.0000000000000632

DO - 10.1097/JTO.0000000000000632

M3 - Article

C2 - 26230972

AN - SCOPUS:84942516354

VL - 10

SP - 1468

EP - 1474

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 10

ER -